Argenx Se (ARGX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval from China’s National Medical Products Administration for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), marking it as the first approved therapy for this condition in China. This approval is seen as a significant advancement for patients who have long been in need of effective treatment options. The decision is based on successful trial results showing a substantial reduction in CIDP relapse risk.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
